About Biocon Our Business Research & Development Biocon's Technology Investors Media Careers CSR
  Press Releases
  Download Center
  Video Gallery
  Photo Gallery
  Media Contacts

Company Statement

Biocon Facilities complete Pre Approval U.S. FDA lnspection

Bengaluru, India, Feb 18, 2019

"This is to inform you that the U.S. FDA concluded two pre approval inspections of Biocon’s manufacturing facilities in Bengaluru.

There were no observations and no Form 483 was issued after the pre-approval inspection of our Oral Solid Dosage Facility conducted between 11th-15th Feb 2019.

The pre-approval inspection of our additional, new injectable manufacturing line for a biologic drug product, conducted between 7th-15th Feb 2019, resulted in a form 483 with two observations. Biocon intends to address these expeditiously.

We remain committed to global standards of Quality and Compliance."

- Company Spokesperson

<< Back




Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2018, Biocon. All Rights Reserved